NOTABLE LABS LTD (NTBL) Fundamental Analysis & Valuation
NASDAQ:NTBL • IL0012002452
Current stock price
0.2479 USD
-0.09 (-27.68%)
At close:
0.2456 USD
0 (-0.93%)
After Hours:
This NTBL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. NTBL Profitability Analysis
1.1 Basic Checks
- NTBL had negative earnings in the past year.
- NTBL had a negative operating cash flow in the past year.
- NTBL had negative earnings in each of the past 5 years.
- In the past 5 years NTBL always reported negative operating cash flow.
1.2 Ratios
- NTBL has a worse Return On Assets (-152.09%) than 86.15% of its industry peers.
- NTBL has a worse Return On Equity (-232.90%) than 71.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -152.09% | ||
| ROE | -232.9% | ||
| ROIC | N/A |
ROA(3y)-70.94%
ROA(5y)-62.1%
ROE(3y)-91.91%
ROE(5y)-81.59%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Gross Margin of NTBL (37.70%) is better than 76.91% of its industry peers.
- NTBL's Gross Margin has declined in the last couple of years.
- The Profit Margin and Operating Margin are not available for NTBL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 37.7% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.15%
GM growth 5Y-8.21%
2. NTBL Health Analysis
2.1 Basic Checks
- NTBL does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, NTBL has more shares outstanding
- The debt/assets ratio for NTBL is higher compared to a year ago.
2.2 Solvency
- NTBL has an Altman-Z score of -16.80. This is a bad value and indicates that NTBL is not financially healthy and even has some risk of bankruptcy.
- With a Altman-Z score value of -16.80, NTBL is not doing good in the industry: 84.55% of the companies in the same industry are doing better.
- A Debt/Equity ratio of 0.03 indicates that NTBL is not too dependend on debt financing.
- With a Debt to Equity ratio value of 0.03, NTBL perfoms like the industry average, outperforming 41.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -16.8 |
ROIC/WACCN/A
WACC10.75%
2.3 Liquidity
- A Current Ratio of 2.77 indicates that NTBL has no problem at all paying its short term obligations.
- With a Current ratio value of 2.77, NTBL is not doing good in the industry: 68.56% of the companies in the same industry are doing better.
- A Quick Ratio of 2.77 indicates that NTBL has no problem at all paying its short term obligations.
- NTBL has a worse Quick ratio (2.77) than 67.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.77 | ||
| Quick Ratio | 2.77 |
3. NTBL Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 65.56% over the past year.
- Looking at the last year, NTBL shows a very negative growth in Revenue. The Revenue has decreased by -34.79% in the last year.
- The Revenue for NTBL have been decreasing by -12.08% on average. This is quite bad
EPS 1Y (TTM)65.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.52%
Revenue 1Y (TTM)-34.79%
Revenue growth 3Y-30.41%
Revenue growth 5Y-12.08%
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to decrease by -63.21% on average over the next years. This is quite bad
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-81.59%
EPS Next 2Y-63.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. NTBL Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for NTBL. In the last year negative earnings were reported.
- Also next year NTBL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as NTBL's earnings are expected to decrease with -63.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-63.21%
EPS Next 3YN/A
5. NTBL Dividend Analysis
5.1 Amount
- NTBL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NTBL Fundamentals: All Metrics, Ratios and Statistics
0.2479
-0.09 (-27.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2024-08-14/amc
Earnings (Next)11-12 2024-11-12/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners16.5%
Ins Owner Change0%
Market Cap2.39M
Revenue(TTM)313.00K
Net Income(TTM)-16.74M
Analysts80
Price Target9.18 (3603.11%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.38%
Min EPS beat(2)-25.98%
Max EPS beat(2)-4.77%
EPS beat(4)0
Avg EPS beat(4)-294.73%
Min EPS beat(4)-1133.4%
Max EPS beat(4)-4.77%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-31.6%
EPS NY rev (1m)0%
EPS NY rev (3m)-27.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 7.65 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.33 | ||
| P/tB | 0.33 | ||
| EV/EBITDA | N/A |
EPS(TTM)-6.91
EYN/A
EPS(NY)-3.63
Fwd EYN/A
FCF(TTM)-1.76
FCFYN/A
OCF(TTM)-1.75
OCFYN/A
SpS0.03
BVpS0.74
TBVpS0.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -152.09% | ||
| ROE | -232.9% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 37.7% | ||
| FCFM | N/A |
ROA(3y)-70.94%
ROA(5y)-62.1%
ROE(3y)-91.91%
ROE(5y)-81.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.15%
GM growth 5Y-8.21%
F-Score1
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 20.83% | ||
| Cap/Sales | 25.56% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.77 | ||
| Quick Ratio | 2.77 | ||
| Altman-Z | -16.8 |
F-Score1
WACC10.75%
ROIC/WACCN/A
Cap/Depr(3y)72.79%
Cap/Depr(5y)45.66%
Cap/Sales(3y)111.54%
Cap/Sales(5y)70.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.52%
EPS Next Y-81.59%
EPS Next 2Y-63.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-34.79%
Revenue growth 3Y-30.41%
Revenue growth 5Y-12.08%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-24.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.33%
OCF growth 3YN/A
OCF growth 5YN/A
NOTABLE LABS LTD / NTBL Fundamental Analysis FAQ
What is the ChartMill fundamental rating of NOTABLE LABS LTD (NTBL) stock?
ChartMill assigns a fundamental rating of 1 / 10 to NTBL.
What is the valuation status of NOTABLE LABS LTD (NTBL) stock?
ChartMill assigns a valuation rating of 0 / 10 to NOTABLE LABS LTD (NTBL). This can be considered as Overvalued.
What is the profitability of NTBL stock?
NOTABLE LABS LTD (NTBL) has a profitability rating of 1 / 10.
What is the financial health of NOTABLE LABS LTD (NTBL) stock?
The financial health rating of NOTABLE LABS LTD (NTBL) is 3 / 10.
What is the earnings growth outlook for NOTABLE LABS LTD?
The Earnings per Share (EPS) of NOTABLE LABS LTD (NTBL) is expected to decline by -81.59% in the next year.